Regulation of the thrombotic potential of atheroma

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 736-741

  Libby, Peter ^a   Mach, François ^b   Schönbeck, Uwe ^b   Bourcier, Todd ^b   Aikawa, Masanori ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN;

ATHEROMA; ATHEROSCLEROSIS; CONFERENCE PAPER; INFLAMMATORY DISEASE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0032741950     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615905     Document Type: Conference Paper

References (60)

1. Ross R. The pathogenesis of artheroselecrosis: a perspective for 1990s. Nature. 1993; 362:801-809.
2. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
3. Fuster V. Mechanisms leading to myocardial infarction: Insights from vascular biology. Circulation. 1994 90:2126-2146.
4. Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619-622.
5. van der Wal A C, Becker A E, van der Loos C M, Das P K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
6. Wilcox J N, Smith K M, Schwartz S M, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci. USA. 1989; 86:2839-2843.
7. Moreno P R, Bernardi V H, Lopez-Cuellar J, Murcia A M, Palacios I F, Gold H K, Mehran R, Sharma S K, Nemerson Y, Fuster V, Fallon J. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation. 1996;94:3090-3097.
8. Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease, Vol. 1, Lippincott-Raven, New York; 1996:585-594.
9. Moreno P R, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994; 90:775-778.
10. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
11. Hansson GK, Jonasson L, Holm J, Clowes MK, Clowes A. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ Res. 1988;63:712-719.
12. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996;149:359-366.
13. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
14. Hansson GK, Jonasson L, Seifert PA, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis. 1989;9:567-578.
15. Fuster V, Badimon I, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med. 1992;326:242-250.
16. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131-138.
17. Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol. 1997;8:301-311.
18. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb. 1992;12:206-211.
19. Gregory SA, Edgington TS. Tissue factor induction in human monocytes: two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J Clin Invest. 1985;76:2440-2445.
20. Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy J-Y, Pober JS, Libby P. Functional CD 40 Ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA.. 1997;94:1931-1936.
21. Laman JD, de Smet BJ, Schoneveld A, van Meurs M. CD40-CD40L interactions in atherosclerosis. Immunol Today. 1997;18:272-277.
22. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 199614:591-617.
23. Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol. 1996;63:43-78.
24. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cells differentiation. J Exp Med. 1992;175:1091-1101.
25. Yellin MJ, Brett J, Baum D, Matsushima A, Szablocs M, Stern D, Chess L. Functional interactions of T cells with endothelial cells: The role of CD40L-CD40-mediated signals. J Exp Med. 1995;182:1857-1864.
26. Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92:4342-346.
27. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simons JC, Denfeld RW, Kiener PA, Aruffo A. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995182:33-40.
28. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-3960.
29. Mach F, Schönbeck U, Fabumni RP, Murphy C, Bonnefoy J-Y, Libby P. Activation of endothelial cells by interaction with T cells induces matrix metalloproteinases through CD40L-CD40 signals: implications for the pathogenesis of atherosclerosis. Am J Pathol. 1999;1:1-9.
30. Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P. Activation of monocyte/macrophage function related to acute atheromata complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
31. Schönbeck U, Herzberg M, Petersen A, Wohlenberg C, Gerdes J, Flad H-D, Loppnow H. Human vascular smooth muscle cells express interleukin-1ß-converting enzyme (ICE), but inhibit processing of the interleukin-1ß precursor by ICE. J Exp Med. 1997;185:1287-1294.
32. Schönbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P. Expression of Stromelysin-3 in atherosclerotic lesions. J Exp Med. 1999;189:1-11.
33. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in a mouse model by interruption of CD40-CD40L signaling. Nature. 1998;394:200-203.
34. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114-3124.
35. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 1991;88:1067-1072.
36. Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA. 1983;80:2956-2960.
37. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost. 1993;71:138-143.
38. Krishnamurti C, Alving BM. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost. 1992;18:67-80.
39. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
40. Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vase Biol. 1996;16:539-545.
41. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998;18:1-6.
42. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
43. Gallicchio M, Hufhagl P, Wojta J, Tipping P. IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol. 1996;157:2610-2617.
44. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA. 1997;94:10335-10340.
45. 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
46. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
47. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996;7:330-335.
48. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97:2433-2444.
49. Aikawa M, Rabkin E, Voglic SJ, Shing H, Nagai R, Schoen FJ, Libby P. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res. 1998;83:1015-1026.
50. Aikawa M. Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, Libby P. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation. In press.
51. Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest. 1996;75:451-461.
52. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
53. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. .Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
54. Aikawa M, Voglic SJ, Rabkin E, Shiomi M, Libby P. An HMG-CoA reductase inhibitor (cerivastatin) suppresses accumulation of macrophages expressing matrix metalloproteinases and tissue factor in atheroma of WHHL rabbits. Circulation. 1998;98:I-47.
55. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. ArteriosclerThromb Vasc Biol. 1997;17:265-272.
56. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1996;137 Suppl:S101-109.
57. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
58. Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranyl-geranylation and Rho proteins. J Am Soc Nephrol. 1998;9:1377-1388.
59. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514.
60. Gelb MH, Scholten JD, Sebolt-Leopold JS. Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol. 1998;2:40-48.